title: [Monoclonal antibody therapy in breast cancer].
abstract: A new trend has been taking place in the daily oncology practice in the past twenty years: we are progressively moving toward individualized and personalized treatments. The treatment of breast cancer is one of the best examples to underline the outstanding effectiveness of the individualized approach. The modern molecular pathology features are capable of predicting the biological behavior of the tumors which gives a new basis for our therapeutic choices, both for neoadjuvant and adjuvant settings, as well as for metastatic disease. In our paper we review the currently used monoclonal antibodies in the treatment of breast cancer and provide an overview of the new research and future directions in this field.
authors.affiliation: I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Onkológiai Részleg, Budapest, Hungary.
authors.forename: Magdolna
authors.initials: M
authors.lastname: Dank
authors.forename: Tímea
authors.initials: T
authors.lastname: Tõkés
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism*; D000068818:Cetuximab; D017024:Chemotherapy, Adjuvant; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D008453:Maytansine / Q000031:analogs & derivatives / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D020360:Neoadjuvant Therapy / Q000379:methods; D000077544:Panitumumab; D000068878:Trastuzumab
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D000068258:Bevacizumab; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068878:Trastuzumab; D000068818:Cetuximab; D000080044:Ado-Trastuzumab Emtansine